Clinical Trial Search

Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After the End of All Study Therapy (SVR12) — 58.3; 90.0 Percentage of participants

Primary: Area Under the Concentration Time-curve From 0 to 24 Hours (AUC0-24) of Grazoprevir — 1.71; 1.42; 1.61; 0.321 uM*hr

Primary: Percentage of Participants Achieving Undetectable HCV RNA 12 Weeks After Completing Study Therapy (SVR12) — 92.4; 94.2; 92.4; 98.1 Percentage of participants — p=<0.001

Primary: Percentage of Participants Achieving Sustained Virologic Response at 12 Weeks After the End of Treatment (SVR12) — 54.2; 84.0; 88.5 percentage of participants

Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUCinf] — 10690; 3187; 2725; 3430 nanogram*hour/milliliter (ng*hr/mL)

Primary: Proportion of Participants With Sustained Virologic Response 12 (SVR-12) — 54; 18 participants — p=.02

Primary: Responses to the Control of Eating Questionnaire — 4.5; 5.2; 5.1; 5.2 units on a scale

Primary: Percentage of Participants Achieving Sustained Virologic Response (SVR) at 12 Weeks After the End of All Study Therapy (SVR12) — 97.1 Percentage of participants

Primary: Baseline Adjusted Hemoglobin A1c Over Time — 9.46; 9.85 percentage of HbA1c — p=0.903

Primary: Determine the Benefit of Oral Vancomycin Therapy for Primary Sclerosing Cholangitis and Biliary Atresia — 10; 0; 0; 0 participants

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 95.5; 87.5 percentage of participants

Primary: Area Under the Plasma Concentration-time Curve for Ticagrelor (AUC 0-12h) — 6307; 9791 ng*h/mL

Primary: Adjusted Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Apixaban — 236; 249; 186 ng/mL

Primary: Evidence of Anterior Chamber Inflammation — 1; 10; 0; 1 participants

Primary: Physical Function — 29.4; 24.2 percentage of subjects